Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FVC · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1261 participantsLow
Findings
What do systematic reviews say?
873 questions · 883 findings · 38 reviews · Cystic Fibrosis and Genetic Disorders
No studies found 319 · 36.1%GRADE not reported 18 · 2%Very low 198 · 22.4%Low 186 · 21.1%Moderate 147 · 16.6%High 15 · 1.7%
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Lung function: FEF25‐75 mL/s (change from baseline) · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1261 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted123 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
HRQoL ‐ change from baseline in CFCS total score and CFQ‐R respiratory domain · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsVery low
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FVC (% predicted) Change from baseline · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs dornase alfa
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young adults with CF
1 finding from 1 review
- no estimate extracted231 participantsVery low
Summary of findings ‐ Inhaled mannitol vs dornase alfa
Lung function: FEV1 mL (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FEV1 mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- MD 2.8231 participantsVery low
Summary of findings ‐ Inhaled mannitol vs dornase alfa
FEV1 % predicted · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ Inhaled mannitol vs dornase alfa
FVC · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- MD 0.14231 participantsVery low
Summary of findings ‐ Inhaled mannitol vs dornase alfa
Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FEF25-75 mL/s (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- no estimate extracted231 participantsVery low
Summary of findings ‐ Inhaled mannitol vs dornase alfa
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
- no estimate extracted231 participantsVery low
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted391 participantsVery low
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Lung function: FEV1 mL (change from baseline) · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1 study · 391 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 % predicted: absolute change from baseline · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1261 participantsLow
Oral azithromycin vs placebo
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
- Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 549 participantsHigh
Oral azithromycin vs placebo
Time to next pulmonary exacerbation · adults and children with cystic fibrosis
1 finding from 1 review
- Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 796 participantsModerate